National Specialized Hospital for Active Therapy of Hematological Diseases

Sofia, Bulgaria

National Specialized Hospital for Active Therapy of Hematological Diseases

Sofia, Bulgaria

Time filter

Source Type

Trpchevska N.,SAGBAL Dr Shterev | Trpchevska N.,National Specialized Hospital for Active Therapy of Hematological Diseases | Dimova I.,SAGBAL Dr Shterev | Dimova I.,Medical University-Sofia | And 8 more authors.
Journal of Assisted Reproduction and Genetics | Year: 2017

Complex chromosome translocations are structural chromosomal rearrangements involving three or more chromosomes and more than two breakpoints. A complex chromosome rearrangement was detected in a phenotypically normal female patient that was referred to the hospital for genetic counseling due to reproductive failure. A cytogenetic evaluation was performed, according to standard method of chromosomal analysis, using G-banding technique. The patient’s karyotype showed a balanced complex chromosome rearrangement (BCCR) involving chromosomes 1, 8, and 11 with three breakpoints 1p31, 8q13, and 11q23. The karyotype designed according to ISCN (2013), is 46,XX,t(1;8;11)(p31;q13;q23) (8qter→8q13::1p31→1qter;8pter→8q13::11q23→11qter;11pter→11q23::1p31→1pter). Additionally, the proband’s mother and brother were tested, resulting in the same exact translocation. In this study, we describe all possible meiotic segregations regarding this translocation, as well as the clinical phenotypes which could arise, if unbalanced products of conception survive. This is a rare case of familial complex chromosome rearrangement, giving a view for its reproductive consequences. © 2017 Springer Science+Business Media New York


Angelova S.,National Specialized Hospital for Active Therapy of Hematological Diseases | Jordanova M.,Children Hospital of Hematological Diseases | Spassov B.,National Specialized Hospital for Active Therapy of Hematological Diseases | Shivarov V.,National Specialized Hospital for Active Therapy of Hematological Diseases | And 11 more authors.
Balkan Journal of Medical Genetics | Year: 2011

Gene amplification (amp) is one of the basic mechanisms connected with overexpression of oncogenes. The c-MYC (located in 8q24) and MLL (located in 11q23) are the most often over represented genes that lead to a rapid proliferation of the affected cell clone in patients with myeloid neoplasms. Assessment of the level of amp c-MYC or amp MLL in the cases with trisomy 8 (+8) or trisomy 11 (+11) and myeloid malignances is necessary for a more precise estimation of the disease progression.A total of 26 patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) were included in the study: 18 with +8, six with +11 and two with complex karyotypes suspected of the partial trisomy. Routine cytogenetic analysis and fluorescent in situ hybridization (FISH) were applied to indicate the chromosome alterations and genes amp in the bone marrow cells.Amp c-MYC was observed in 12 from 18 (66.7%) patients with +8. All the patients with +11 demonstrated a different level of amp MLL. In most of the cases with MDS (9/10), the coincidence of the +8 or +11 with amp c-MYC or amp MLL, respectively, leads to transformation to AML and/or short overall survival. Our data suggest that amp c-MYC and amp MLL develop in conformity with +8 and +11, especially in cases with progressive deviations in the karyotype as an aggressive expansion of an aberrant cell clone and appearance of additional chromosome anomalies.


Angelova S.,National Specialized Hospital for Active Therapy of Hematological Diseases | Spassov B.,National Specialized Hospital for Active Therapy of Hematological Diseases | Nikolova V.,National Specialized Hospital for Active Therapy of Hematological Diseases | Christov I.,Medical University-Pleven | And 2 more authors.
Cytology and Genetics | Year: 2015

The aim of our study was (1) to define if the amplification of c-MYC, MLL and RUNX1 genes is related to the progressive changes of the karyotype in patients with AML and MDS with trisomy 8, 11, and 21 (+8, +11, and +21) in bone marrow and (2) can that amplification be accepted as part of the clonal evolution (CE). Karyotype analysis was performed in 179 patients aged 16–81 with AML or MDS with different chromosomal aberrations (CA). The findings were distributed as follows: initiating balanced CA (n = 60), aneuploidia (n = 55), unbalanced CA (n = 64). Amplification of c-MYC, MLL and RUNX1 genes by means of fluorescence in situ hybridization (FISH) was found in 35% (7 out of 20) of AML and MDS patients with +8, +11, and +21 as a single CA in their karyotype; in 63.6% of the pts (7 out of 11)—with additional numerical or structural CA and in 75% (9 out of 12)—with complex karyotype. We assume that the amplification of the respective chromosomal regions in patients with +8, +11, and +21 is related to CE. Considering the amplification as a factor of CE, we established 3 patterns of karyotype development depending on the type of the initiating CA in it. Significant statistical differences were found between the three patterns regarding the karyotype distribution in the different stages of progression (p < 0.001). © 2015, Allerton Press, Inc.


Angelova S.,National Specialized Hospital for Active Therapy of Hematological Diseases | Spassov B.,National Specialized Hospital for Active Therapy of Hematological Diseases | Nikolova V.,National Specialized Hospital for Active Therapy of Hematological Diseases | Christov I.,Medical University-Pleven | And 2 more authors.
Cytology and Genetics | Year: 2015

The aim of our study was to assess if the type of primary chromosomal aberrations (CA) of the karyotype of patients with Acute myeloid leukemia (AML) and Myelodysplastic syndromes (MDS) determines the way and the rate of karyotype development. Conventional cytogenetic analysis was carried out on 248 AML and 105 MDS patients at diagnosis. Clonal evolution (CE) was found in 40% (51 of 128) of AML patients and in 47.5% (19 of 40) of MDS patients having CA in their karyotype. The first pattern we established was for the most frequent CA which initiate CE in 28 patients with a complex karyotype. These CA were non-balanced rearrangements in the following regions: 5q, 7q, 11q, 3q, monosomy 5, monosomy 7. The second pattern of CE was regarding the most frequent aneuploidias (+8, +11, +21, −Y), and the third pattern concerned balanced CA. We found significant difference in the distribution of karyotypes in different stages of progression between the first and the other two groups (p < 0.001). No statistical difference was found between the patterns in the second and the third group CA (p > 0.5). © 2015, Allerton Press, Inc.


PubMed | National Specialized Hospital for Active Therapy of Hematological Diseases
Type: Journal Article | Journal: Balkan journal of medical genetics : BJMG | Year: 2013

Gene amplification (amp) is one of the basic mechanisms connected with overexpression of oncogenes. The c-MYC (located in 8q24) and MLL (located in 11q23) are the most often over represented genes that lead to a rapid proliferation of the affected cell clone in patients with myeloid neoplasms. Assessment of the level of amp c-MYC or amp MLL in the cases with trisomy 8 (+8) or trisomy 11 (+11) and myeloid malignances is necessary for a more precise estimation of the disease progression. A total of 26 patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) were included in the study: 18 with +8, six with +11 and two with complex karyotypes suspected of the partial trisomy. Routine cytogenetic analysis and fluorescent in situ hybridization (FISH) were applied to indicate the chromosome alterations and genes amp in the bone marrow cells. Amp c-MYC was observed in 12 from 18 (66.7%) patients with +8. All the patients with +11 demonstrated a different level of amp MLL. In most of the cases with MDS (9/10), the coincidence of the +8 or +11 with amp c-MYC or amp MLL, respectively, leads to transformation to AML and/or short overall survival. Our data suggest that amp c-MYC and amp MLL develop in conformity with +8 and +11, especially in cases with progressive deviations in the karyotype as an aggressive expansion of an aberrant cell clone and appearance of additional chromosome anomalies.

Loading National Specialized Hospital for Active Therapy of Hematological Diseases collaborators
Loading National Specialized Hospital for Active Therapy of Hematological Diseases collaborators